Turner Adrianna M, Kinsella Paul, Miller William R, Carter Glen P, Tran Truc T, Howden Benjamin P, Arias Cesar A
Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Microbiology Department, Royal Melbourne Hospital, Melbourne, Australia.
Antimicrob Agents Chemother. 2025 Oct;69(10):e0106024. doi: 10.1128/aac.01060-24. Epub 2025 Sep 11.
Difficult-to-treat (DTR) enterococcal infections, particularly those caused by multidrug-resistant and , pose significant clinical challenges due to limited treatment options and high rates of treatment failure, compounded by a paucity of new antimicrobial agents in the development pipeline. Despite advances in understanding resistance mechanisms and synergistic antibiotic combinations, robust clinical data to guide therapy for severe or DTR enterococcal infections remain limited. This review synthesizes available evidence to inform optimal management strategies, including drug selection and dosing, while highlighting areas needing further research. Given the ongoing threat posed by multidrug-resistant enterococci, we emphasize the importance of gathering robust clinical data to guide best practices for managing these difficult-to-treat infections.
难治性(DTR)肠球菌感染,尤其是由多重耐药菌引起的感染,由于治疗选择有限、治疗失败率高,加上研发中的新型抗菌药物匮乏,给临床带来了重大挑战。尽管在理解耐药机制和联合抗生素协同作用方面取得了进展,但用于指导严重或难治性肠球菌感染治疗的有力临床数据仍然有限。本综述综合了现有证据,以提供最佳管理策略的信息,包括药物选择和剂量,同时突出需要进一步研究的领域。鉴于多重耐药肠球菌持续构成的威胁,我们强调收集有力临床数据以指导管理这些难治性感染的最佳实践的重要性。